Compare Heron Therapeutics Inc (HRTX) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Ryanair Holdings plc — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Ryanair Holdings plc trades at $54.16 (market cap $27.95B). The key difference: Ryanair Holdings plc is far larger — about 377.5× Heron Therapeutics Inc's market cap, and Ryanair Holdings plc pays a 1.6% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Ryanair Holdings plc for 72 Days on average.
| HRTX | RYAAY | |
|---|---|---|
Market Cap | $74.04M | $27.95B |
Volume | 3,668,095 | 1,519,820 |
Sector | Health | Industrials |
52-Week High | $1.49 | $73.82 |
52-Week Low | $0.27 | $51.95 |
Typical Hold Time | 35 Days | 72 Days |
Enterprise Value | $180.78M | $25.00B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
RYAAY trades at $56.00 with a slight 0.24% daily gain, showing mixed technical signals amid bearish moving averages but neutral oscillators. Fundamentally, the airline maintains strong profitability with 12.13% net margins and attractive valuation multiples (P/E 13.95, EV/EBITDA 6.22), though recent Q3 2026 earnings are pending against high expectations. Analyst sentiment leans bullish with 65% buy ratings, but news highlights fuel cost pressures and Boeing MAX 10 certification delays as near-term concerns.
The stock presents a value opportunity given low valuations and robust cash flow, but investors face headwinds from oil price volatility and operational challenges. Upside hinges on Q3 earnings beat and cost management, while downside risks include prolonged certification delays and weaker winter traffic. Institutional ownership trends and dividend stability ($0.44 upcoming) provide support, but macro uncertainties warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
